The most commercially significant downstream conversion of telpegfilgrastim API is aseptic filling into 1.0 mL siliconised borosilicate glass syringes containing 6 mg active protein in 0.6 mL solution, equivalent to a protein concentration of 10 mg/mL for the reference PEGylated G-CSF injection format. The formulation is compounded in a stainless steel jacketed vessel at 2–8°C with 10 mM acetic acid buffer, 30 mg/mL sorbitol and 0.02 mg/mL polysorbate 20, adjusted to pH 4.0. Bulk hold time in the formulation vessel is generally capped at 18–24 h at 2–8°C because extended hold times with slow agitation can increase subvisible particle counts when silicone oil droplets migrate from glass barrel surfaces. The fill-finish line uses a rotary piston pump with a fill-volume tolerance of ±0.02 mL; peristaltic pumps are avoided because of protein adsorption to tubing and pulsation-related foaming. Bulk solution is passed through a 0.22 µm PVDF membrane filter immediately before filling under Grade A laminar flow. Filled syringes receive fluoropolymer-coated butyl rubber stoppers and are inspected by automated visual inspection for visible particulates according to USP <790>, while subvisible particulate counts are controlled under USP <787>. Container closure integrity is verified using helium leak and dye-ingress methods aligned with USP <1207>. Syringe dimensions and glass performance are controlled under ISO 11040-6:2012. Terminal product type is a single-dose prefilled syringe protected from light and stored at 2–8°C; no terminal sterilisation is applied because the protein denatures above 30°C and terminal gamma irradiation would generate free radicals that cleave the PEG-protein conjugate.

Why Does Auto-Injector Assembly Require a Separate Container Closure Integrity Strategy?

During auto-injector assembly, the filled primary container is inserted into a mechanically driven device that adds spring-actuation force to the plunger rod; this mechanical load changes the risk profile for glass breakage, silicone oil droplet migration and plunger movement. The drug product itself retains the 6 mg/0.6 mL formulation described above, and no additional dilution or reformulation occurs at device assembly. Device functional testing follows ISO 11608-5:2022, covering activation force, extended needle length, delivered dose volume, injection time and needle safety guard deployment. Because the device applies axial force on the plunger, the filled syringe must meet break-loose and glide force requirements typically verified on a texture analyser; published product-specific force values for telpegfilgrastim presentations are limited, so transfer protocols commonly establish ranges during installation qualification with the selected device platform. The assembly process includes loading the filled syringe into the device housing, verifying spring position, and performing 100% visual inspection for exposed needle and trigger engagement. Container closure integrity after assembly is retested under USP <1207> because the primary closure may be deliberately moved during device activation; helium leak testing is typically conducted before and after simulated actuation. The resulting finished presentation is a single-dose auto-injector or on-body injector, with storage labels requiring 2–8°C up to patient administration and a limited excursion window at 15–30°C before injection.

When Thermally Controlled Secondary Packaging Is Qualified, Which Fill-Volume and Temperature Tolerances Govern Patient-Ready Syringes?

Once the filled syringe has passed release testing, it enters secondary packaging in insulated shippers with phase-change material to maintain 2–8°C during transport. The syringe remains a 6 mg/0.6 mL single-dose presentation; no concentration adjustment or additive is introduced at this stage. Packaging qualification follows WHO guidance in WHO TRS 961 Annex 9 and International Safe Transit Association standard ISTA 7E for insulated shipping containers; thermal mapping data must show min/max excursions within 2–8°C for the declared transport duration of 48–72 h. The downstream process consists of conditioning phase-change materials, loading syringes into prequalified polyurethane-insulated shippers, inserting calibrated data loggers, and conducting winter and summer ambient profile tests. Fill volume is inseparable from packaging because syringes with 0.6 mL nominal fill volume cannot be reconstituted or diluted at hospital level; therefore weight checks during packaging verify that no leakage or plunger movement occurred during transport. Packaged output is a cold-chain qualified, patient-ready single-dose syringe packed in a single-patient carton and labelled with a tamper-evident seal.

Batch release of telpegfilgrastim bulk drug substance for injectable conversion requires control of PEGylation-related impurities that arise during N-terminal conjugation of PEG reagent to the G-CSF protein. The conjugation step in bulk API manufacturing is typically operated at a PEG-to-protein molar feed ratio of 1.1:1 to 1.3:1 to maximise mono-PEGylated species while limiting di- and tri-PEGylated variants; published telpegfilgrastim-specific conjugation stoichiometry is limited, so transfer protocols often verify the ratio using size-exclusion high-performance liquid chromatography peak integration and reverse-phase purity. Downstream purification uses cation-exchange chromatography to remove unconjugated protein and free PEG reagent, followed by ultrafiltration/diafiltration through a 10 kDa membrane to reduce residual PEG and buffer-exchange the bulk protein into formulation-compatible acetate buffer. Specifications are established under ICH Q6B decision trees for characterisation and consistency of biotechnology-derived products; process validation of the purification train is performed under ICH Q7 for active pharmaceutical ingredients. The isolated output is a frozen bulk drug substance at −20°C or −70°C, released on the basis of pH, protein concentration, PEGylation profile, residual free PEG, host-cell protein, and bacterial endotoxin. Temperature excursions above −20°C during storage can increase dePEGylation and aggregation; repeated freeze-thaw cycles beyond one are specified as non-routine deviation because of particle formation.

Oral Multiparticulate Capsules for Nonclinical Gastrointestinal Screening

Proteolytic degradation in the gastric environment prevents the use of conventional tablet, capsule, or granule presentations for commercial PEGylated G-CSF products; the oral-grade API designation therefore appears in research batch production for nonclinical bioavailability screening rather than marketed oral dosage forms. In this screening track, telpegfilgrastim is incorporated into fluidised-bed granules at 0.5–2.0 mg active protein per capsule using mannitol and hydroxypropyl methylcellulose acetate succinate as matrix former and enteric polymer. Enteric coating is applied to a weight gain of 8–12% w/w to target release at pH 5.5 or higher; dissolution testing uses USP <711> apparatus II with simulated gastric fluid pH 1.2 for the acid stage and simulated intestinal fluid pH 6.8 for the buffer stage. Nonclinical safety and pharmacokinetic studies for biotechnology-derived proteins are designed under ICH S6(R1), which addresses species relevance, immune response and study duration for biological products; human oral bioavailability data for telpegfilgrastim is limited. The downstream production process consists of top-spray fluid-bed granulation, milling, enteric coating in a Wurster column, encapsulation into size 3 hard gelatin or HPMC capsules, and characterised dissolution release. The resulting article is a research-grade enteric-coated multiparticulate capsule used exclusively in animal pharmacokinetic and proof-of-concept studies; it is not a registered commercial dosage form and must not be referenced as a patient-ready product.

Forced Degradation Studies and Stability Data Packages for Injectable Registration

Regulatory stability submissions for telpegfilgrastim injectable presentations require forced degradation and long-term stability protocols executed under ICH Q1A(R2) and ICH Q5C conditions. The reference liquid formulation maintains the 10 mg/mL protein concentration with the acetate-sorbitol-polysorbate 20 vehicle described for the prefilled syringe; API spiking into placebo is not recommended because excipient exposure must be representative of the final product. Forced degradation conditions include thermal stress at 40°C/75% RH, acid hydrolysis at pH 3.0, base hydrolysis at pH 9.0, oxidation with 0.1% hydrogen peroxide, and light exposure under ICH Q1B; the purposeful degradation is monitored by size-exclusion chromatography, reverse-phase HPLC, subvisible particle counting, and capillary electrophoresis. The downstream production process for the stability data package is a cGMP batch release activity rather than physical formulation: samples are pulled from one commercial-scale batch, placed in qualified chambers, and assayed at predefined time points up to 24 months for long-term 2–8°C storage. The final deliverable is a regulatory stability data package and characterised reference material linking API batch identity to finished product quality attributes. Operational limits include no shaking of syringes for transport and no freezing at −20°C because ice crystal damage increases subvisible particle counts under USP <787>.